ClinicalTrials.gg
RecruitingNCT04899102Updated Dec 18, 2025

Intermittent Fasting for NAFLD in Adults

An interventional study of Time-Restricted, Intermittent Fasting in Fatty Liver, Intermittent Fasting and Fatty Liver, Nonalcoholic, sponsored by Massachusetts General Hospital. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-18.

Primary conditionNon-alcoholic Fatty Liver DiseaseRegistry: Fatty LiverReclassifiedWhy we changed it
Registry
Fatty Liver — the first condition term the registry derived for this study.
ClinicalTrials.gg
Non-alcoholic Fatty Liver Disease
Why
  1. The study's listed conditions name Non-alcoholic Fatty Liver Disease, a narrower term within Fatty Liver.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Massachusetts General Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2026, 3 months ago, but the record still lists the study as recruiting.
  • Started Feb 2022; still recruiting 4 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
25
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 16 studies in Non-alcoholic Fatty Liver Disease by Massachusetts General Hospital — 2 open to participants now, 3 under way, 1 of them phase 3. Non-alcoholic Fatty Liver Disease · Massachusetts General Hospital.

Planned enrollment
9th of 15
25 · median 40
Started
2022
with 1 other
No phase
9 of 16
1 open now
Registered
13th of 16
by date

Among the 16 studies in Non-alcoholic Fatty Liver Disease by Massachusetts General Hospital, this one is the 9th largest by planned enrollment of the 15 interventional ones that give a count, is one of 2 that started in 2022, is one of 9 with no phase, and was the 13th registered.

Non-alcoholic Fatty Liver Disease

1,618 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.

Browse Non-alcoholic Fatty Liver Disease studies →

Open to participants now

2 of the 16 studies in Non-alcoholic Fatty Liver Disease by Massachusetts General Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Non-alcoholic Fatty Liver Disease by Massachusetts General Hospital, or all of them as a file.
02

Study summary

NAFLD is a growing threat to public health. Currently, there is a significant need for highly effective treatments for NAFLD. Non-obese NAFLD (BMI\<30kg/m2) is an increasingly recognized condition, sometimes described as "lean NAFLD". Intermittent Fasting (IF) may be uniquely beneficial in non-obese NAFLD. The purpose of this study is to identify non-pharmacologic, lifestyle-based methods of NAFLD treatment within non-obese adults.

Read the detailed description

Nonalcoholic fatty liver disease (NAFLD), which encompasses a spectrum from simple steatosis and steatohepatitis (NASH) to fibrosis and cirrhosis, is the leading cause of liver disease in the United States. There are currently no FDA-approved pharmacologic therapies for NAFLD and NASH, and standard low-calorie diets are often minimally effective, difficult to adhere to and to maintain. Thus, continued investigation of strategies to treat NAFLD and NASH is greatly needed. Non-obese NAFLD (BMI\<30kg/m2) is an increasingly recognized condition, sometimes described as "lean NAFLD". It is estimated that 10-20% of American and Europeans without obesity have this condition. There is a pressing need for the study of lifestyle interventions independent of weight loss to treat this important subset of NAFLD patients. This protocol aims to investigate the utility of time restricted, intermittent fasting (TRF) as a potential method. Adults with non-obese NAFLD are at risk of progression to end-stage liver disease and development of cardiometabolic disease. Intermittent Fasting (IF) may be uniquely beneficial in non-obese NAFLD. IF is characterized by periods of dietary restriction leading to metabolic production and use of ketones from adipocytes rather than hepatically-derived glucose.

The goal of this study is to learn if time-restricted, intermittent fasting can help reduce the amount of fat in the liver in adults with non-alcoholic fatty liver disease (NAFLD). Ideally, this study will yield more information about time-restricted, intermittent fasting as a potential lifestyle-based treatment for adults with NAFLD and a body mass index (BMI) between 23-30 kg/m\^2.

03

Conditions studied

  • Fatty Liver
  • Intermittent Fasting
  • Fatty Liver, Nonalcoholic
  • Non-Alcoholic Fatty Liver Disease
  • Liver Fat

Browse trials for

Keywords

  • Fatty Liver
  • Intermittent Fasting
  • Non-obese
  • Diet
  • Nutrition
  • Time-restricted
  • Liver Fat
  • Non-Alcoholic Fatty Liver Disease
  • Fatty Liver, Nonalcoholic
04

In context

Non-alcoholic Fatty Liver Disease Reclassified

1,618 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.

This study's planned enrollment of 25 is below the median of 60 across 1,176 interventional studies indexed under Non-alcoholic Fatty Liver Disease.

Browse Non-alcoholic Fatty Liver Disease studies →

Lead sponsor

Massachusetts General Hospital is the lead sponsor of 2,591 studies on the registry; 445 are open to participants now.

Of its 224 completed or terminated interventional studies of FDA-regulated products, 168 (75%) have results posted.

Compared within Non-alcoholic Fatty Liver Disease, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Fatty Liver. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Willing and able to provide
  2. Age 18 years or older at time of consent
  3. 23-30kg/m\^2 at screening
  4. Evidence of NAFLD confirmed by historical procedure obtained no more than 6 months prior to the screening visit, defined as:

    • Grade >=1 steatosis on clinical liver ; OR
    • Fatty liver on validated imaging modality (non-contrast CT scan, MR Spectroscopy, MRI proton density fat fraction, ultrasound)
  5. Liver fat fraction ≥10% on H-MRS performed during the screening period
  6. antibody and surface antigen negative at screening

Exclusion criteria

Exclusion Criteria:

  1. Heavy alcohol use for at least 3 consecutive months within the past 5 years prior to screening [heavy alcohol consumption is defined as: > 20g daily for women or > 30mg daily for men, assessed by the Lifetime Drinking History assessment at screening (23, 24)].
  2. Evidence of other known forms of chronic liver disease including:

    • Alcoholic liver disease, , , PBC, PSC, hepatitis, Wilson disease, iron overload, alpha-1-antitrypsin deficiency, drug-induced liver injury, known or suspected hepatocellular carcinoma (HCC).
  3. Current or prior history of Type II Diabetes requiring insulin or sulfonylureas due to risk of hypoglycemia with fasting.
  4. Use of any pharmacological treatments for NAFLD/NASH within the 6 months prior to the screening visit, except vitamin E. Patients on a stable dose of vitamin E can be enrolled in the study.
  5. Unstable body weight [defined as: >10% reduction in body weight in the 6 months prior to the screening visit]
  6. Known cirrhosis, stage 4 fibrosis on prior liver , or clinical evidence of cirrhosis or portal hypertension on imaging or exam.
  7. Current or prior history of score ≥7.
  8. History of liver transplant, or current placement on a liver transplant list.
  9. Known positivity for infection.
  10. Prior or planned bariatric surgery, patients on active pharmacological treatment for weight loss, or active involvement in a weight loss program.
  11. Routine MRI exclusion criteria, such as the presence of a pacemaker or cerebral aneurysm clip.
  12. Chronic Kidney Disease (CKD) with \< 60.
  13. For women of (WOCBP): positive urine hCG, trying to achieve pregnancy, or breastfeeding [a negative urine pregnancy test is required at screening for women of child-bearing potential].
  14. Other medical conditions or severe chronic illnesses that, in the opinion of the Investigator, may present a to study participation.
  15. Any other condition that, in the opinion of the Investigator, may hinder study compliance or completion of the study schedule of assessments.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

06

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
25 participants (estimated)

Study arms

  • Experimental
    Time-Restricted, Intermittent Fasting Group

    Special type of diet for 6 weeks, called time-restricted, intermittent fasting.

    Behavioral: Time-Restricted, Intermittent Fasting

Interventions

  • BehavioralTime-Restricted, Intermittent Fasting

    A special type of diet for 6 weeks, called time-restricted, intermittent fasting.

07

What researchers measure

Primary outcomes

  1. Liver Fat Content

    Liver Fat Content as measured by hydrogen-magnetic resonance spectroscopy (H-MRS)

    Time frame: change from baseline to 6 weeks

Secondary outcomes

  1. ≥30% Relative Liver Fat Reduction Proportion

    Proportion of subjects with a ≥30% relative reduction in hepatic fat

    Time frame: change from baseline to 6 weeks

  2. Visceral Adipose Tissue Content

    Visceral Adipose Tissue Content as measured by magnetic resonance imaging/magnetic resonance spectroscopy (MRI/MRS)

    Time frame: change from baseline to 6 weeks

  3. Quality of Life Score

    Quality of Life Score as measured by Chronic Liver Disease-NAFLD questionnaire (CLDQ-NAFLD)

    Time frame: change from baseline to 6 weeks

  4. Dietary Intake

    Dietary Intake as measured by caloric intake and nutrient contents, assessed by ASA24

    Time frame: change from baseline to 6 weeks

08

Study locations

1 of 1 sites recruiting
09

References and documents

Individual participant data

Plan to share: Yes — Final Research Data, with all patient identifiers removed, will be available to other researchers through request to the PI. Because information contained in the final research data will include multiple demographic and biological variables that could potentially be used in concert to identify participants, it will be shared only under a Data Sharing Agreement that includes (1) a commitment to using the data only for research purposes and not to identify any individual participant and (2) a commitment to destroying or returning the data after analyses are completed.

Supporting information: Study protocol

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2022 (actual). Primary completion is estimated for Jul 2026, 53 months after the start.

Of 356 non-industry interventional studies with no phase under Non-alcoholic Fatty Liver Disease, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 51. This study's planned 53 months is above that.

Counting every sponsor, half of 384 studies reached it within 25 months; a quarter within 12 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
May 19, 2021
First posted
May 24, 2021
StartActual
Feb 1, 2022
Primary completionEst.
Jul 31, 2026
CompletionEst.
Jul 31, 2026
Last update
Dec 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04899102
Responsible party
Kathleen E Corey (Director, Fatty Liver Clinic Assistant Professor, Harvard Medical School, Massachusetts General Hospital) — Principal investigator
First posted
May 24, 2021
Start date
Feb 1, 2022
Primary completion
Jul 31, 2026 (estimated)
Completion
Jul 31, 2026 (estimated)
Last update
Dec 18, 2025

Study contacts

Kathleen E Corey, MD/MPH
Contact
kathleen.corey@mgh.harvard.edu
6177265925
Jenna Gustafson, MS
Contact
JLGustafson@mgh.harvard.edu
6177243836
Kathleen Corey, MD
principal investigator · Massachusetts General Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion